Research and Clinical Trials

Title  
Lilly I4T-MC-JVCY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Brief Description  
Part A Objective: The primary objective of Part A is to assess the safety and tolerability of ramucirumab when administered in combination with erlotinib as therapy in previously untreated patients with EGFR mutation-positive metastatic NSCLC. Part B: Primary Objectives: The primary objective of Part B is to compare PFS of ramucirumab administered in combination with erlotinib versus placebo in combination with erlotinib as therapy in previously untreated patients with EGFR mutation-posit
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Lung
Status  
OPEN
Start Date  
04/01/2016
IRB Number  
00014244
Principal Investigator  
Mileham, Kathryn Finch
Contact Name  
Sandra Samu-Arce

For More Information, Contact  Sandra  , Samu-Arce
Phone:  980-993-5484 Fax:    
Email:  Sandra.SamuArce@carolinashealthcare.org
Address:1550 Faulk Street Suite 1500 Monroe, 28112
Close